Skip to content
Screener

Cullinan Therapeutics, Inc. CGEM Total Liabilities & Equity

Total Liabilities & Equity at other companies

Eli Lilly logo
Eli LillyLLY
$142.28B+41.0%
Johnson & Johnson logo
Johnson & JohnsonJNJ
$201.06B+4.0%
Amgen logo
AmgenAMGN
$95.64B+8.8%
Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
$41.73B+9.2%
CTO
Citius Oncology, Inc.CTOR
$100.7M+10.1%
Vor Biopharma logo
Vor BiopharmaVOR
$506.75M+364%

Other financials

Income statement

See full
Revenue-
Operating income-$57.3M+24.5%
Net income-$53.7M+23.3%
EPS (diluted)-$0.69+24.2%

Balance sheet

See full
Cash & equivalents$78.6M+8.0%
Total debt$2.1M+36.3%
Total equity$408.7M-30.8%
Total assets$363.8M-30.1%

Cash flow

See full
Operating cash flow-$38.2M+33.7%
CapEx$11.0K
Free cash flow-$38.1M-4.1%

Valuation

See full
Market cap$1.14B+165%
Enterprise value$1.06B+196%

Profitability

See full
Operating margin-358.7%
Net margin-346.1%

Returns & leverage

See full
Return on equity-44%+26.2pp
Debt / equity0.0×
Current ratio8.4×-1.4×

Where this comes from

Reported directly by Cullinan Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:LiabilitiesAndStockholdersEquity.

The source filing: Cullinan Therapeutics, Inc.’s 10-Q, filed August 6, 2026.

Filed
Aug 6, 2026, 7:10 AM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001193125-26-336717
Line itemJune 30, 2026December 31, 2025
Stockholders' equity:
Preferred stock, $0.0001 par value, 10,000,000 shares authorized as of June 30, 2026 and December 31, 2025; 204,209 and 555,935 shares issued and outstanding as of June 30, 2026 and December 31, 2025, respectively.
Common stock, $0.0001 par value, 150,000,000 shares authorized as of June 30, 2026 and December 31, 2025; 64,345,770 and 60,244,136 shares issued and outstanding as of June 30, 2026 and December 31, 2025, respectively66
Additional paid-in capital1,013,366995,823
Accumulated other comprehensive income (loss)(134)1,020
Accumulated deficit(691,484)(588,119)
Total stockholders' equity321,754408,730
Total liabilities and stockholders' equity$363,787$448,374

Item 1. Financial Statements.

FAQ

What is Cullinan Therapeutics, Inc.'s total liabilities & equity?
Cullinan Therapeutics, Inc. (CGEM) reported total liabilities & equity of $363.79M in Q2 2026.
How has Cullinan Therapeutics, Inc.'s total liabilities & equity changed year-over-year?
Cullinan Therapeutics, Inc.'s total liabilities & equity decreased by 30.1% year-over-year, from $520.33M to $363.79M.
What is the long-term trend for Cullinan Therapeutics, Inc.'s total liabilities & equity?
Over 5 years (2020 to 2025), Cullinan Therapeutics, Inc.'s total liabilities & equity has grown at a 15.9% compound annual growth rate (CAGR), from $214.71M to $448.37M.
What does total liabilities & equity mean?
Total assets = total liabilities + total equity. This must always balance — a fundamental accounting identity.

Ask your AI about Cullinan Therapeutics, Inc.'s total liabilities & equity.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude